WINDLAS
OVERVALUEDWindlas Biotech Limited
Pharma · NSE
↓ 20.1% vs fair value
52W Low
₹697
+9.4% from low
52W High
₹1,140
-33.1% from high
Valuation Gauge
Current Price
₹763
Fair Value
₹635
Fair Value Analysis
₹635
Based on earnings growth potential for Pharma sector companies | ROCE improving (latest 17.5%) — capital allocation becoming more efficient. | COVID-resilient: PAT dropped from ₹64Cr (FY2019) to ₹16Cr (FY2020) during COVID but has fully recovered.
Growth Valuation
100% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Financially Healthy
Profitability
ROE of 12.5% is acceptable for Pharma sector (benchmark: 18%)
Debt & Leverage
D/E ratio of 0.1x is well within the Pharma sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 24.1x trades at a 43% discount to Pharma sector median (42x) — attractively valued
Cash Flow
FCF margin of 2.1% — thin cash generation, watch capex trends
Earnings Growth
5yr EPS CAGR of 17.0% is in line with the Pharma sector average of 15.3%
Dividend
Dividend yield of 0.8% provides moderate shareholder returns
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
-0.4%
Free cash flow / market cap
Revenue Growth (YoY)
+19.5%
Year-on-year revenue change
Profit Growth (YoY)
-6.3%
Year-on-year PAT change
Operating Cash Flow
₹68 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹31.8
P/E Ratio
24.1x
P/B Ratio
3x
ROE
12.5%
ROCE
16.5%
Debt / Equity
0.06x
Beta
0.22
Div Yield
0.8%
FCF (Cr)
₹16 Cr
Revenue (Cr)
₹755 Cr
EPS Growth 5Y
17%
Mkt Cap (Cr)
₹1,611 Cr
52W High
₹1,140
52W Low
₹697.4
Book Value/Share
₹254
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹868 Cr | ₹105 Cr | 12.0% | ₹67 Cr | ₹31.77 |
| 2025-03-31 | ₹760 Cr | ₹94 Cr | 12.0% | ₹61 Cr | ₹29.10 |
| 2024-03-31 | ₹631 Cr | ₹78 Cr | 12.0% | ₹58 Cr | ₹27.98 |
| 2023-03-31 | ₹513 Cr | ₹60 Cr | 12.0% | ₹43 Cr | ₹20.04 |
| 2022-03-31 | ₹466 Cr | ₹52 Cr | 11.0% | ₹38 Cr | ₹17.48 |
| 2021-03-31 | ₹428 Cr | ₹55 Cr | 13.0% | ₹16 Cr | ₹24.69 |
| 2020-03-31 | ₹329 Cr | ₹34 Cr | 10.0% | ₹16 Cr | ₹25.28 |
| 2019-03-31 | ₹307 Cr | ₹38 Cr | 12.0% | ₹64 Cr | ₹99.55 |
| 2018-03-31 | ₹352 Cr | ₹39 Cr | 11.0% | ₹11 Cr | ₹20.04 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Pharma| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Par Drugs And Chemicals Limited | ₹86 | ₹469.7 | +81.7% | 7.3 | 15.4% | FAIRLY_VALUED |
IOL Chemicals and Pharmaceuticals Limited | ₹79.5 | ₹237.8 | +66.6% | 19.6 | 5.2% | FAIRLY_VALUED |
Kilitch Drugs (India) Limited | ₹132.7 | ₹321 | +58.7% | 17.7 | 9.4% | UNDERVALUED |
Bal Pharma Limited | ₹69 | ₹147.5 | +53.2% | 12.8 | 12.6% | FAIRLY_VALUED |
Zydus Lifesciences | ₹868 | ₹1,502.2 | +42.2% | 17.6 | 19.9% | UNDERVALUED |
Natco Pharma | ₹1,030 | ₹1,597 | +35.5% | 11.8 | 18.0% | UNDERVALUED |
Jagsonpal Pharmaceuticals Limited | ₹190.6 | ₹275.2 | +30.7% | 30.8 | 20.1% | UNDERVALUED |
Lupin | ₹2,280 | ₹3,112 | +26.7% | 22.4 | 23.8% | UNDERVALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Company Documents
Annual reports, concall transcripts & regulatory filings
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant